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suMMARy – depression has been associated with various cardiovascular risk factors such as hypertension, obesity, 
atherogenic dyslipidemia and hyperglycemia. in depressive disorder, hyperactivity of the hypothalamic-pituitary-adrenal 
(hpA) axis and changes in the immune system have been observed. on the other hand, somatic diseases such as obesity, 
hyperlipidemia, hypertension and diabetes mellitus type 2 are now perceived as important comorbid conditions in patients 
with depression. The pathogenesis of the metabolic syndrome and depression is complex and poorly researched; however, 
it is considered that the interaction of chronic stress, psychotrauma, hypercotisolism and disturbed immune functions 
contribute to the development of these disorders. The aim of the study was to investigate the relationship between de-
pression and metabolic syndrome regarding the hpA axis dysfunction and altered inflammatory processes. literature 
search in Medline and other databases included articles written in english published between 1985 and 2012. Analysis of 
the literature was conducted using a systematic approach with the search terms such as depression, metabolic syndrome, 
inflammation, cytokines, glucocorticoids, cortisol, and hpA axis. in conclusion, the relationship between depression and 
metabolic syndrome is still a subject of controversy. further prospective studies are required to clarify the possible causal 
relationship between depression and metabolic syndrome and its components. furthermore, it is important to explore the 
possibility of a common biologic mechanism in the pathogenesis of these two disorders, in which special attention should 
be paid to the immune system function, especially the possible specific mechanisms by which cytokines can induce and 
maintain depressive symptoms and metabolic disorders. The data presented here emphasize the importance of recognition 
and treatment of depressive disorders with consequent reduction in the incidence of metabolic syndrome, but also the need 
of regular search for metabolic disorders and their treatment to avoid all of these adverse effects and maybe reduce the 
incidence of depressive disorders.
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Introduction
depression is associated with various cardiovascu-
lar risk factors such as hypertension, obesity, athero-
genic dyslipidemia, hyperglycemia, smoking, and 
excessive use of alcohol and other psychoactive sub-
stances. sleep disturbances, changes in the autonomic 
nervous system, hyperactivity of the hypothalamic-
pituitary-adrenal (hpA) axis and changes in the im-
mune system were observed in depressive disorder. 
on the other hand, somatic diseases such as obesity, 
hyperlipidemia, hypertension and diabetes mellitus 
type 2 are ever more perceived as important comorbid 
conditions in patients with depression. it is still not 
clear whether these disorders are parts of the patho-
logic process or the consequences of treatment. how-
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ever, ever more data show that severe mental illnesses 
have an impact on physical health, and only recently 
researches in the field of psychiatry have begun to 
observe this situation in the context of the metabolic 
syndrome. The pathogenesis of the metabolic syn-
drome and depression is complex and poorly under-
stood, however, it is considered that the interaction 
of chronic stress, psychotrauma, hypercortisolism and 
disturbed immune function contributes to the devel-
opment of these disorders1-7.
Metabolic Syndrome
Metabolic syndrome is a complex disorder con-
sisting of several components: abdominal obesity, 
dyslipidemia, hypertension, and abnormal glucose 
metabolism8. Although the components of the meta-
bolic syndrome are often pronounced enough to ex-
pect overlapping among them, they show clustering 
more frequently than it could be interpreted just as 
a coincidence9. Moreover, the syndrome is associated 
with proinflammatory and prothrombotic states aris-
ing from the secretory activity of adipose tissue, and 
is characterized by elevated levels of proinflammatory 
cytokines, endothelial dysfunction, hyperfibrinogen-
emia, increased platelet aggregation, elevated concen-
trations of plasminogen activation inhibitors, elevated 
concentrations of uric acid, and microalbuminuria. 
Metabolic syndrome represents the greatest risk of 
diabetes and cardiovascular diseases. Metabolic syn-
drome has been described in patients with polycystic 
ovary syndrome, non-alcoholic hepatic steatosis, mi-
croalbuminuria, and chronic renal failure8-11.
Pathophysiology
Metabolic syndrome is a common disorder sig-
nificantly related with age that is probably due to 
the increased prevalence of obesity. Central obesity, 
measured by waist circumference, is considered es-
sential because of the strong evidence linking waist 
circumference with cardiovascular disorders and other 
components of metabolic syndrome, and it is likely 
that central obesity is an initial step in the etiologic 
cascade that leads to insulin resistance and meta-
bolic syndrome. however, the exact cause remains 
unknown and probably includes several different fac-
tors, many of which are related to lifestyle changes. 
Certainly, development of the syndrome is boosted by 
increasing visceral fat, sedentary lifestyle, increased 
caloric intake and dietary habits. These environmental 
factors are likely to interact with predisposing genetic 
factors that are believed to be linked to insulin resis-
tance, obesity and chronic low grade inflammation. 
Although any of these three situations hypothetically 
could be the starting point, they are so intertwined 
that making such a distinction is very difficult or even 
not possible9,12-16.
obesity is increasing worldwide and abdominal 
obesity, according to many authors, is the real cause 
of the metabolic syndrome. Abdominal obesity is a 
common finding in people with metabolic syndrome; 
about 60% of people with metabolic syndrome are 
obese, while only 10%-20% have elevated morning 
blood glucose levels. however, metabolic syndrome 
can occur in people who are not obese; in one study, 
5%-10% of the population with body mass index 
(bMi) of 20-25 kg/m2 had metabolic syndrome. Al-
though they were not clearly overweight, they had in-
creased visceral fat deposits. The distribution of body 
fat, particularly visceral adipose tissue accumulation, 
which increases with age, was significantly associated 
with insulin resistance and significantly correlated 
with many of diabetogenic, atherogenic, prothrom-
botic and proinflammatory metabolic abnormali-
ties17-21. The results of other studies have shown that 
visceral fat decreases significantly faster than subcuta-
neous adipose tissue in response to weight loss. This 
observation may help explain why even modest weight 
loss (5%-10%) in the obese can lead to clinically sig-
nificant improvements in numerous metabolic param-
eters and blood pressure17.
Adipose tissue plays an important role in insulin 
action in humans. Metabolic activity is mainly medi-
ated by enhanced lipolysis and increased concentra-
tions of free fatty acids (ffA). ffA in the muscle 
directly inhibit glucose transport and glycogen syn-
thesis, increase excretion of glucose and very low 
density lipoprotein (vldl) from the liver, and re-
duce the secretion of insulin from the pancreas22-25. 
impaired insulin action in muscle tissue can be in-
creased by ffA activity of the blood vessels, where 
they reduce the synthesis of nitric oxide and thereby 
disrupt the action of insulin-mediated vasodilata-
tion26. Metabolic changes associated with increased 
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total body fat mass and its anatomical distribution are 
not only caused by lipolysis and ffA secretion, but 
also are the result of changes in the secretion of nu-
merous factors that affect insulin action, such as lep-
tin, the main function of which is regulation of food 
intake and energy expenditure in the central nervous 
system (Cns), resistin that acts antagonistically to the 
sensitivity to insulin, and adiponectin, the concentra-
tion of which was negatively correlated with obesity 
and glucose tolerance27. As the levels of ffA and re-
sistin are higher and the levels of adiponectin lower, 
insulin resistance is more pronounced17. besides the 
secretion of ffA, the increased mass of adipose tissue 
contributes to insulin resistance via the formation of 
inflammatory conditions in the body. Adipose tissue 
is a major source of inflammatory mediators such as 
tumor necrosis factor α (tnf-α) and interleukin 6 
(il-6). tnf-α inhibits the tyrosine kinase insulin 
receptors, while il-6 enhances hepatic gluconeogen-
esis, resulting in hyperglycemia and compensatory 
hyperinsulinemia. According to the results of some 
studies, elevated concentrations of il-6 in plasma in 
combination with low concentrations of adiponectin 
are associated with an increased risk of developing 
diabetes24,25,28.
insulin exerts strong influence on the regulation 
of metabolism of very low density (vldl), high den-
sity (hdl) and low density (ldl) lipoprotein. in the 
states of insulin resistance, the secretion of vldl in 
the liver is increased and degradation by lipoprotein 
lipase (lpl) is reduced, so that hypertriglyceridemia 
develops as a result of increased hepatic vldl se-
cretion and abnormal peripheral elimination17,20. 
impaired lipolysis of lipoproteins leads to reduced 
concentrations of hdl, so that a typical atherogenic 
triad consisting of hypertriglyceridemia, low hdl 
cholesterol and elevated levels of atherogenic ldl 
cholesterol is present in insulin resistance17,24,25,29. it 
is considered that hypertriglyceridemia is a central 
metabolic defect that leads to a cascade of events that 
ultimately produce the atherogenic lipid profile17.
Diagnosis
According to the nCep Atp-iii criteria, the di-
agnosis is based on the simultaneous occurrence of 
three or more of the following: waist circumference 
>102 cm in men or >89 cm in women, triglycerides 
≥1.7 mmol/l, hdl-cholesterol <1.04 mmol/l in 
men or <1.3 mmol/l in women, systolic blood pres-
sure ≥130 mm hg or diastolic pressure ≥85 mm hg, 
and morning glucose ≥6.11 mmol/l. The use of an-
tihypertensive drugs or oral hypoglycemic therapy is 
considered in the criteria for high blood pressure and 
high morning blood glucose concentration30. 
Dysfunction of the Hypothalamic-Pituitary-
Adrenal Axis and the Metabolic Syndrome
disturbance of the hpA axis is a common finding 
in patients with metabolic syndrome. Adipose tissue 
is no longer seen as a passive store of energy but as 
a highly active endocrine gland that synthesizes and 
secretes many hormones, cytokines and growth fac-
tors. More researches give a key role to cortisol in con-
trolling the physiology of adipose tissue and suggest a 
reciprocal relationship between hpA axis and adipose 
tissue. Cortisol plays an important role in regulating 
the metabolism of glucose, amino acids, fatty acids, 
distribution of energy, and redistribution of body fat.
impairment in the synthesis of adrenal hormones 
has an important effect on changes in food intake, 
glucose and lipid metabolism, and energy balance. 
The combination of some genetic variants with envi-
ronmental factors such as increased food intake, lack 
of physical activity and chronic stress leads to impair-
ment of the regulatory mechanisms of adrenal cortisol 
synthesis, secretion, degradation, and conversion of 
inactive cortisone to cortisol. hpA axis activity and 
acute reactions to stress are controlled by the inhibi-
tory feedback loop that is executed via glucocorticoid 
receptors located in the hippocampus, prefrontal cor-
tex and hypothalamus. Acute stress, which is char-
acterized by significant but transient rise in cortisol 
concentrations, induces mobilization of fatty acids 
and decreases food intake, and has no adverse con-
sequences for the body. on the other hand, moderate 
but sustained chronic stress is associated with inap-
propriate secretion of cortisol, central obesity and en-
docrine, metabolic and hemodynamic abnormalities. 
Chronically elevated cortisol levels redistribute fat 
from the subcutaneous depot in visceral adipose tis-
sue, increase food intake (stress eating), and during 
prolonged stress induce secretion of leptin as well as 
leptin resistance leading to decrease in the reduction 
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of food intake induced by leptin. Thus, increased cor-
tisol concentrations due to chronic stress favor food 
intake and visceral fat accumulation, thereby promot-
ing the occurrence of metabolic syndrome.
it has already been pointed out that the secretion 
of cortisol from the adrenal gland is normally regu-
lated via hpA axis, but it can be regulated occasion-
ally by the mechanisms independent of the adreno-
corticotropic hormone (ACth). Thus, cortisol can be 
synthesized locally by converting inactive cortisone 
to cortisol. such local production occurs primarily in 
the visceral adipose tissue. in the presence of insu-
lin, cortisol inhibits lipid mobilization in adipocytes 
leading to accumulation and retention of triglycerides. 
As the density of glucocorticoid receptors is higher 
in the intra-abdominal adipose tissue than in other 
fat depots, the activity of cortisol leads to accumula-
tion of fat in visceral adipose tissue, development of 
abdominal obesity, and insulin resistance. Although 
the metabolic syndrome can mimic Cushing’s syn-
drome, obese patients generally have normal or sub-
normal plasma cortisol concentrations. This could 
be explained by the increased exposure of fat cells to 
cortisol in adipose tissue, which means that the ac-
cumulation of triglycerides in visceral adipose tissue 
may be caused, at least in part, by the local synthesis 
of cortisol in the organs sensitive to insulin and corti-
sol including adipose tissue, liver and skeletal muscles. 
After initial changes, these disorders induce positive 
feedback that contributes to the maintenance of these 
systems in an activated state in the form of an end-
less spiral: more cortisol in the systemic or local levels 
leads to accumulation of fat in adipocytes, which leads 
to insulin resistance. Thus, impaired regulation of ad-
renal cortisol synthesis in the interaction with hpA 
axis hyperactivity may be involved in the development 
of obesity, insulin resistance, metabolic syndrome and 
its consequences21,31-37.
over the past few decades, shortening of sleep has 
become a very common annoyance in industrialized 
countries. This trend towards shorter sleep occurs 
during the same period of a dramatic increase in the 
prevalence of obesity and diabetes. Current evidence 
suggests a close link between endocrine, metabolic, 
cardiovascular and immune functions and sleep disor-
ders. in studies on young healthy persons exposed to 
recurrent partial sleep restrictions, the increase in hun-
ger and appetite was observed, which led to overeat-
ing and weight gain, and was correlated with reduced 
glucose tolerance and insulin sensitivity and reducing 
circulating levels of the anorexigenic hormone leptin, 
while at the same time boosting the levels of the orex-
igenic hormone ghrelin. on the other hand, chronic 
sleep loss or disturbances in the periodicity are corre-
lated with altered circadian rhythm of cortisol secre-
tion and secretion of growth hormone associated with 
sleep, both of which are associated with the temporal 
pattern of abnormal glucose tolerance with long-term 
consequences of developing obesity. Chronic stress 
and sleep disorders are associated with hyperactivity 
of adrenal glands, resulting in the increased cortisol 
secretion, induction of food intake and weight gain, 
which in turn leads to insulin resistance21.
Proinflammatory Cytokines and Metabolic 
Syndrome
Morbid obesity is associated with low-grade sys-
temic inflammation and immune activation23,38-42. 
Although low-grade chronic inflammation may be 
the major pathogenetic factor for the development of 
metabolic syndrome, the link between inflammation 
and metabolic syndrome is still unclear. factors such 
as increased caloric intake, increased intake of ma-
cronutrients, physical inactivity and aging can lead, 
through expansion of adipose tissue and overproduc-
tion of cytokines, to insulin resistance, metabolic syn-
drome and diabetes in genetically and metabolically 
predisposed individuals17,24,25,43. Macrophage infiltra-
tion in adipose tissue can be the first step in maladap-
tive reaction to prolonged excessive intake of food that 
leads to a vicious circle with the production of cytok-
ines and other mediators of inflammation23. visceral 
adipose tissue produces a number of proinflamma-
tory cytokines. Macrophages located in adipose tis-
sue are responsible for the almost complete synthesis 
of tnf-α and a significant amount of il-69,17,44-48. 
increased synthesis of il-6, resistin and tnf-α, as 
a reflection of the expansion of adipose tissue infil-
trated by monocytes, results in insulin resistance and 
lipolysis of triglycerides in circulating ffA. A num-
ber of inflammatory genes and genes specific for mac-
rophages are significantly expressed in white adipose 
tissue in rodents43,49. The fact that this occurs before 
the development of insulin resistance supports the hy-
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pothesis that proinflammatory cytokines originating 
from adipose tissue have a causal relationship with the 
development of metabolic syndrome50.
one of the potentially most important mediators 
of inflammation is tnf-α, a multifunctional cy-
tokine with numerous roles in the immunomodula-
tory and inflammatory reactions. tnf-α is a protein, 
which got its name from the initial identification as a 
proapoptotic factor in tumor cells, and additionally it 
has a role in the development of cachexia (alternative 
name cachectin). The role of tnf-α in obesity was 
first noticed in 1993 on several models of mice with 
obesity or type 2 diabetes. A similar increased produc-
tion of tnf-α in adipose tissue and direct correlation 
between the increased synthesis of tnf-α, obesity 
and insulin resistance is found in obese individuals. in 
humans, tnf-α from adipose tissue is not secreted 
into the circulation but it acts locally as a paracrine 
and autocrine factor. There are various mechanisms by 
which tnf-α affects insulin sensitivity in fat cells: 
it reduces expression of the genes involved in insulin 
action, disrupts signaling through insulin receptors, 
and acts antagonistically on the transcription fac-
tors in adipose tissue that regulate insulin sensitivity. 
tnf-α from adipose tissue also causes diabetogenic 
effects in obesity indirectly through stimulation of li-
polysis in adipocytes, leading to increased secretion of 
ffA in the circulation, which in turn has adverse ef-
fects on insulin sensitivity. The finding that obesity is 
associated with excessive expression of tnf-α and its 
negative effects on insulin sensitivity raises the ques-
tion of why our bodies react in such an unproduc-
tive way. part of the answer could be found through 
an evolutionary perspective. over millions of years, 
our bodies have been adapted to cope with situations 
where food supply is scarce and unpredictable. There 
is an evolutionary advantage in gene expression that 
effectively saves energy (energy sparing gene hypoth-
esis). in such circumstances, it is understandable that 
tnf-α serves as a regulator of energy homeostasis. in 
the states of shorter periods of excessive calorie intake, 
excessive tnf-α expression in adipose tissue reduces 
the sensitivity to insulin, leading to reduced glucose 
and fatty acid uptake. Also, by reducing lpl activity, 
tnf-α inhibits lipid storage in adipose tissue. These 
mechanisms together foster an increased concentra-
tion of circulating fatty acids that are used by muscle 
tissue in energy expenditure. in the modern lifestyle 
characterized by constant excessive intake of energy 
rich food, secretion of tnf-α becomes maladaptive 
and fosters development of diabetes and atherosclero-
sis17,23,38,50.
C-reactive protein (CRp) is an independent risk 
factor at all levels of severity of the metabolic syn-
drome and its level increases with the number of the 
metabolic syndrome components51. even more, CRp 
may be predictive for the metabolic syndrome de-
velopment42. Although it is not as predictive for car-
diovascular diseases as cholesterol, hypertension or 
smoking, CRp appears as the most important among 
the newly discovered risk factors indicating a greater 
predictive power than other markers of inflammation 
such as il-652.
il-6 is generally considered as a proinflammatory 
cytokine and its concentration increases in response 
to inflammation. however, some recent researches 
suggest that one of the major functions of il-6 is to 
decrease the inflammatory response primarily by in-
hibiting secretion of tnf-α and il-1β. il-6 is also 
the subject of sleep-wake cycles with increased output 
during the night53. in humans, 35% of the basal con-
centration of il-6 originates from adipose tissue, it is 
secreted directly into the circulation, and besides the 
inflammatory and immune reaction, il-6 is involved 
in many biologic processes such as maintenance of nor-
mal glucose homeostasis and body metabolism, brain 
function and fatigue9,53. during different metabolic 
requirements, the contribution of individual tissues in 
the secretion of il-6 is also changing, such as skeletal 
muscles that become a major source of il-6 synthesis 
after exercise53. While the levels of il-6 increase 18 
times during exercise, the level in the cerebrospinal 
fluid remains stable, suggesting that cerebrospinal 
il-6 is separated from serum il-654. it is possible that 
the increased secretion of il-6 during exercise acts as 
a mediator of improved muscle metabolism and insu-
lin sensitivity throughout the body. in healthy sub-
jects, acute il-6 secretion stimulated by exercise plays 
an important role in maintaining normoglycemia and 
helps deliver adequate nutrients for working muscles. 
in this context, il-6 may be part of a mechanism of 
improving insulin sensitivity induced by exercise53. 
several studies report positive correlation between 
il-6, obesity and insulin resistance as well as with 
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bMi, but the levels of il-6 tend to increase with 
age, as well as in insulin resistance and type 2 diabe-
tes, which may partly explain the observed correla-
tions. however, studies show that chronic elevation 
of il-6 may promote insulin resistance in the liver 
and fat cells. increasing obesity in overweight and 
sedentary individuals may be the result of chronic 
excessive secretion of il-6. il-6 increases lipolysis 
in obesity and contributes to increased serum lev-
els of ffA and hypertriglyceridemia. These negative 
effects of il-6 will continue to be strengthened by 
inactive lifestyle. Results of previous studies suggest 
an important but still not fully comprehended role of 
il-6 in the regulation of glucose and lipid metabo-
lism in the body38,53,55.
Dysfunction of the Hypothalamic-Pituitary-
Adrenal Axis in Depression
different impairments of neuroendocrine regula-
tion have been reported in mood disorders, and corre-
lation between increased secretion of cortisol and de-
pression is one of the oldest observations in biological 
psychiatry. in about 50% of patients with depression, 
elevated cortisol levels can be found. furthermore, el-
evated concentrations of the corticotrophin-releasing 
hormone (CRh), which is frequently found in the ce-
rebrospinal fluid, may be the result of CRh receptor 
desensitization in corticotroph cells. because of the 
elevated basal cortisol concentration, secretory re-
sponse of ACth to CRh is limited, but also because 
of the constant hyperactivity of hpA axis gradually 
comes to adrenocortical hyperplasia making adrenal 
gland hypersensitive to ACth. other mechanisms 
unrelated to ACth, such as neural sympathetic fac-
tors or humoral immune system factors, may also con-
tribute to dissociation between ACth and cortisol in 
depression56-58.
Although genetic predisposition may be necessary 
for the development of affective disorders, stressful 
life events often serve as a trigger for the onset of ill-
ness. long-term exposure to stress and high levels of 
cortisol induce atrophy and loss of cells that contain 
corticosteroid receptors in the hippocampus, which 
are responsible for cortisol-induced suppression of 
CRh-secreting neurons in the paraventricular nucle-
us. elevated levels of cortisol affect glucose transport 
in the hippocampal pyramidal neurons, foster cyto-
solic calcium elevation, and may contribute to the ac-
cumulation of free radicals by reducing the maximum 
capacity of antioxidant enzymes. besides, elevated 
levels of cortisol reduce proliferation of glial cells and 
lead to changes in glial glutamate metabolism and 
may promote vulnerability of neurons via excitotoxic 
processes through upregulation of the N-methyl-
d-aspartate (nMdA) and α-amino-3-hydroxy-4-
isoxasolepropionic acid (AMpA) glutamate receptors. 
to avoid these adverse consequences, the cascade of 
biochemical changes that constitutes an adaptive re-
sponse to stress must be effectively stopped. numer-
ous afferent fibers from different regions of the brain 
are involved in the regulation of hpA axis activities 
in stress conditions, as well as the negative feedback 
mechanism mediated by cortisol from adrenal gland, 
acting on corticosteroid receptors located in differ-
ent regions of the brain (pituitary, hypothalamus and 
limbic areas)56-63. negative feedback mechanisms that 
stop the stress caused by hpA axis hyperactivity are 
impaired in depressed patients; however, there is no 
proper answer yet to explain the mentioned endo-
crine abnormalities. The possible causes are malfunc-
tion of the glucocorticoid receptors in depression and 
impaired functioning of the systems involved in the 
regulation of gene expression of corticosteroid recep-
tors64,65.
The role of the brain serotonin (5ht) in regulat-
ing the hpA activity was investigated greatly, but 
there is no consensus of opinions except that it rep-
resents an important regulatory component of hpA 
axis activity in response to stress. increased activ-
ity of hpA axis actually coincides with changes in 
the 5ht system including enhanced transmission, 
upregulation of postsynaptic 5ht2 receptors, and 
down-regulation of 5ht1A receptors. The same 
changes were observed in depression. perhaps the 
most important aspect of the 5ht system is related 
to the negative feedback action of cortisol. The nega-
tive feedback mechanism of cortisol is done via re-
ceptor sites localized in hypothalamic neurons, sep-
tum, amygdala and reticular formation. innervation 
of these areas is enabled by efferent noradrenergic fi-
bers from locus ceruleus and serotonergic fibers from 
raphe nuclei. Cortisol increases the concentration of 
5ht synthesis and alters the dynamics of secretion 
and reuptake of 5ht57,58.
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Proinflammatory Cytokines in Depressive Disorder
from the psychoneuroimmunologic perspective, 
brain is no longer considered a privileged organ com-
pletely separated from the circulating immune cells 
by the blood-brain barrier, which has a reduced or 
altered immunoreactivity. it is now clear that many 
interactions occur between the neurologic, immune 
and neuroendocrine system66. since most cytokines 
are relatively large hydrophilic molecules, they do not 
pass the blood-brain barrier under physiological con-
ditions. yet, there are places where there is no barrier, 
such as the circumventricular area, or where it is less 
restrictive, such as the organum vasculosum of lami-
nae terminalis and median eminence, in which areas 
the passive transport of cytokines from the blood into 
the brain parenchyma is possible. furthermore, the 
blood-brain barrier integrity may be damaged by trau-
ma or pathologic conditions that can lead to increased 
influx of various inflammatory cells and molecules, 
including cytokines. Moreover, cytokines themselves 
can contribute to damage to the blood-brain barrier, 
which is especially true for tnf-α. furthermore, the 
mechanism of active transport with cytokine-specific 
transport molecules may be involved in the transfer 
of cytokines through the barrier. After entering the 
brain parenchyma, peripheral cytokines bind to the 
assumed receptors on the surface of different cells, in-
cluding microglia, astrocytes and neurons. in addition 
to passing through the blood-brain barrier, cytokines 
can bind to receptors on vascular endothelial cells and 
thus induce the activation of second messengers such as 
nitric oxide (no) and prostaglandins, which can pro-
vide an indirect mechanism of signaling in the Cns. 
Another possible indirect route for cytokine-mediated 
communication between the immune system and the 
brain is signaling through the vagus. Activation of af-
ferent vagal fibers transmits signals from cytokines to 
specific brain nuclei, such as nucleus tractus solitarius, 
which is located in the medulla oblongata, which then 
serve as a relay station to the other brain nuclei in-
cluding the paraventricular nucleus in the hypothala-
mus. in addition to infiltration or indirect signaling 
from the periphery, cytokines and their receptors are 
synthesized in the brain under the influence of elevat-
ed cortisol levels, mainly in astrocytes and microglia. 
furthermore, the synthesis of cytokines in glial cells 
can be triggered by antigenic stimuli such as viral in-
fections, local and peripheral inflammatory responses, 
and brain injuries. it is also assumed that under cer-
tain circumstances, neurons are able to secrete cytok-
ines. The synthesis of cytokines was found in several 
brain regions, including the circumventricular area, 
hypothalamus, hippocampus, cerebellum, basal gan-
glia, and nuclei in medulla oblongata. Although the 
exact role of the central synthesis of cytokines is not 
yet understood, it is thought that proinflammatory 
cytokines, including il-6 and tnf-α, contribute to 
neurodevelopmental and neuroplastic processes, syn-
aptogenesis and recovery of tissues58,66-68. numerous 
studies have shown that cytokines, including tnf-α, 
modulate glutamate-dependent synaptic plasticity69,70. 
Although most researches suggest that tnf-α has 
detrimental effects on synaptic plasticity, recent evi-
dence shows that low physiological levels of tnf-α 
may be important in brain development and in regu-
lating synaptic plasticity. The secretion of tnf-α in 
glial cells in response to reduced neuronal activity 
increases the number of synaptic glutamate AMpA 
receptors, and thus synaptic strength, while the re-
moval of tnf-α leads to weakening of synapses. it is 
possible that a delicate balance between physiological 
and pathophysiological levels of tnf-α is important 
in these processes, so that in physiological conditions 
low levels of tnf-α serve as a modulator of synap-
tic plasticity, and in pathological conditions, when 
the central tnf-α levels become elevated, there are 
harmful apoptotic effects58.
The concept of two-way communication between 
the immune system and the Cns has led to the ques-
tions whether the immune system except for immune 
processes is involved in the neuropathologic processes 
such as depression66. in 1991, smith proposed the 
macrophage theory of depression, according to which 
an increased secretion of cytokines from macrophages 
may explain the majority of depressive symptoms and 
endocrine changes during depression67,71. in 1999, 
Maes proposed a model of depression in which de-
pression is associated with activation of the inflam-
matory response. According to this model, depression 
can be considered as a psychoneuroimmune disease 
in which the peripheral immune activation is respon-
sible for a number of behavioral, neuroendocrine and 
neurochemical changes associated with depression72. 
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This assumption is also described as a cytokine hy-
pothesis of depression73. Characteristics of immune 
system activation in a depressive disorder include in-
crease in the number of circulating lymphocytes and 
phagocytes, elevated serum concentrations of positive 
acute phase proteins such as haptoglobin and CRp, 
as well as increased secretion of proinflammatory cy-
tokines. proinflammatory cytokines such as il-6 and 
tnf-α, which are secreted during the immune re-
sponse and inflammation, activate the central stress 
system components, lead to changes in the activity 
of neurotransmitter network, and induce weakness, 
drowsiness, fatigue, loss of appetite, and decreased li-
bido, suggesting a potential link between depression 
and activation of inflammatory responses58,67,68,74-78.
psychological stress is a common risk factor for 
developing depressive disorders and most of the first 
episodes of depression are preceded by a recognizable 
stressor. in chronic stress, constantly elevated CRh 
and consequently higher levels of cortisol and proin-
flammatory cytokines induce resistance to cortisol ac-
tion in the Cns and on the immune cells in the pe-
riphery interrupting the negative feedback mechanism 
of cortisol – CRh – proinflammatory cytokines. hpA 
axis tends to uncontrolled activation and the immune 
system to the proinflammatory state68. Chronic stress 
increases the level of proinflammatory cytokines such 
as il-6 and tnf-α and their signaling pathways cen-
trally and peripherally, while simultaneously reducing 
the level of normal neuroprotective and growth fac-
tors. This action starts a cascade of molecular events 
that favor the inflammatory and apoptotic mecha-
nisms that can damage cellular plasticity, or even 
survival of neurons, and lead to consequent changes 
in the functioning of the monoaminergic system. el-
evated circulating concentrations of proinflammatory 
cytokines can disrupt synaptic plasticity and cognitive 
processes; patients with depression showed prominent 
deficits in explicit memory and cognitive capacities 
that depend on the hippocampus and medial tempo-
ral lobes. in addition, findings that centrally present 
tnf-α and il-1 play an important role in the regula-
tion of synaptic plasticity enhance the possibility that 
maintaining the intricate balance between the physi-
ologic and pathologic levels of these cytokines plays 
an important role in the complex pathophysiology of 
depressive disorders58,74,79-84.
depression is characterized by disturbances in no-
radrenergic and serotonergic neurotransmission. hy-
pothetical activation of the immune system may be 
causally associated with impairments in these signal-
ing processes. proinflammatory cytokines may lead 
to changes in noradrenergic and serotonergic neu-
rotransmission in brain regions that are thought to 
be involved in the pathogenesis of depression, such as 
the hypothalamus, hippocampus, amygdala, nucleus 
accumbens and prefrontal cortex. The effect of cytok-
ines on the serotonergic system is reflected in reduced 
activity of presynaptic 5ht neurons as a reflection of 
reduced 5ht synthesis, changes in 5ht reuptake in 
the synaptic cleft, and in changes of postsynaptic 5ht 
receptors. The synthesis of 5ht in the highest degree 
depends on the availability of precursor tryptophan in 
the brain. Cytokines reduce the availability of tryp-
tophan by activation of indoleamine-2,3-dioxygenase 
(ido), an enzyme that metabolizes tryptophan into 
kynurenine. Thus, excessive stimulation of ido may 
lead to a decrease in tryptophan serum levels, which is 
accompanied by a significant reduction of 5ht syn-
thesis. low availability of tryptophan in the brain may 
represent a major cause of serotonin deficits which ac-
company depressive disorder. The development and 
severity of depressive symptoms, especially depressed 
mood, anorexia and loss of concentration in patients 
on immunotherapy was positively correlated with the 
decrease in plasma tryptophan concentrations during 
treatment. furthermore, proinflammatory cytokines 
enhance 5ht transmission, which can lead to rapid 
depletion of reserves in conditions when the presynap-
tic 5ht availability is low due to reduced synthesis of 
5ht66. peripheral immune activation can also result 
in positive regulation of serotonin transporters lead-
ing to the depletion of extracellular 5ht and change 
in the number and sensitivity of postsynaptic recep-
tors. These changes may affect the 5ht transmission 
and may thus represent a possible cause of serotoner-
gic impoverishment in depressive disorder66,74,75.
it was observed that the occurrence of depressive 
and anxiety symptoms after cytokine induced stimu-
lation of ido, which converts tryptophan to kynure-
nine, except for the consequence of reduced avail-
ability of tryptophan in the brain and decreased 5ht 
synthesis, can be caused by increased synthesis of 
ido metabolites mediated by kynurenine way, such 
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as 3-hydroxy-kynurenine (3oh-Kyn) and quinolin-
ic acid (Quin), which are neurotoxic substances that 
are present in several neurodegenerative conditions 
such as parkinson’s disease. An increased synthesis 
of these kynurenine metabolites was also observed in 
psychiatric disorders such as anxiety and depression. 
3oh-Kyn can lead to overproduction of free oxygen 
radicals as well as to the increased activity of mono-
amine oxidase (MAo). overproduction of oxygen 
radicals may adversely affect the function and density 
of serotonergic and catecholaminergic receptors by 
inducing changes in membrane viscosity. increased 
MAo activity results in a lower concentration of 5ht 
and catecholamines. Therefore, apart from the direct 
reduction of 5ht availability, ido may contribute to 
the monoaminergic disturbances that are observed in 
depression in an indirect manner45,66. Thus, it appears 
that exogenous administration of proinflammatory 
cytokines may induce depressive symptoms at least 
in part through the modulation of monoaminergic 
transmissions66. Moreover, kynurenine metabolites 
by stimulating of hippocampal nMdA receptors can 
promote tissue damage contributing in this way to the 
pathogenesis of depressive disorders74,82.
Researches in the past 30 years and more sug-
gest an association between depressive disorders and 
vulnerability to various diseases. Conditions such as 
acute and chronic infections are accompanied by de-
pression. The immune system is activated in response 
to infection, and if such activation is systemic, the 
body typically shows symptoms common to depressive 
episodes such as weakness and a variety of behavioral 
responses including decreased appetite, weight loss, 
fatigue, sleep disturbances, psychomotor retardation, 
reduced interest in physical and social environment, 
loss of libido, impairment of cognitive abilities, dys-
phoria, irritability, depressed mood, and anhedonia. 
depressive symptomatology, which is associated with 
other diseases such as multiple sclerosis, Alzheimer’s 
disease, huntington’s disease, parkinson’s disease and 
other neurodegenerative diseases, may not be solely a 
psychological reaction to pain, distress and disability 
associated with a somatic disease, but may be caused 
by direct activation of the immune system and secre-
tion of cytokines from microglia (il-1, il-6, il-8, 
tnf-α and ifn-β)58,66,68, which may affect neuro-
degenerative processes through the synthesis of free 
radicals and toxic kynurenine metabolites that are 
present in many neurodegenerative diseases. in addi-
tion to central mechanisms, inflammatory condition 
can be activated by peripheral mechanisms such as 
atopic dermatitis. Women with allergic symptoms are 
at an increased risk of depression, furthermore, the 
presence of atopy doubles their risk of developing de-
pression later in life. A higher incidence of depression 
or depressive symptoms was observed in rheumatoid 
arthritis, cancer, lupus (systemic lupus erythemato-
sus), and cardiovascular diseases67,68,74,85.
however, these symptoms are not observed only 
during infection or other somatic diseases, but also 
occur after systemic or central administration of cy-
tokines. treatment of patients with oncologic, auto-
immune and infectious diseases, which often involves 
treatment with proinflammatory and antiviral cytok-
ines (il, tnf-α, ifn-α), is associated with depres-
sive symptoms and flu-like symptoms and cognitive 
disorders. The most common side effects of cytokine 
therapy, those which occur early in the course of treat-
ment, usually within two weeks, include flu-like symp-
toms such as fever, malaise, headache and myalgia. 
psychiatric side effects typically occur later in treat-
ment, within 1-3 months, involving dysphoria, de-
pressed mood, irritability, anhedonia, anxiety, fatigue, 
anorexia, weight loss, changes in sleep, psychomotor 
retardation, loss of social interaction and libido, and 
abnormal cognitive capabilities. While the symptoms 
which are flu-like retreat with continued treatment, 
psychiatric side effects can only disappear after dis-
continuation of therapy or with the administration of 
antidepressants66-68,75. The fact that cytokine therapy is 
often accompanied by negative psychiatric symptoms 
that disappear after cessation of therapy or after anti-
depressant administration suggests a potential causal 
role of cytokines in the etiology and pathophysiol-
ogy of various behavioral, psychological and cognitive 
symptoms of depression58,66,76. in a research of interfer-
on use in infectious diseases and cancer, the prevalence 
of the major depressive disorder development ranged 
from 30% to 50%, depending on the dose86-89.
proinflammatory state may be responsible for de-
pressive symptoms but may play a broader role of a 
common denominator among various psychiatric and 
somatic disorders89. identification of a common de-
nominator among the nosologic entities that have not 
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been pathophysiologically linked, such as depression, 
schizophrenia, Alzheimer’s disease, atopic dermatitis, 
rheumatoid arthritis, Crohn’s disease, psoriasis and 
myocardial infarction, may have epistemologic and 
therapeutic implications68. The division to somatic and 
mental diseases is perhaps a mistake that needs to be 
reconsidered71,91. The possibility that different chronic 
diseases may be manifestations of a common individual 
proinflammatory predisposition emphasizes the impor-
tance of the holistic approach that brings a new chal-
lenge for pharmacological research to find strategies for 
recovery of neuro-endocrine-immune homeostasis68.
Relationship between the Immune and 
Neuroendocrine Factors in Depression
The proinflammatory cytokines tnf-α, il-1 
and il-6 are the primary stimulators of hpA axis 
and have a key role in activating hpA axis in depres-
sion66,67. They activate cortisol secretion acting direct-
ly at three levels of hpA axis: hypothalamic, pituitary 
and adrenergic. At the central level, they stimulate 
the secretion of CRh in the hypothalamic paraven-
tricular nuclei. il-6 is a potent stimulator of CRh 
synthesis, which leads to increased hpA axis activ-
ity characterized by increasing levels of cortisol. since 
il-6 stimulates the secretion of ACth and cortisol 
to the levels above the maximal stimulation achieved 
by CRh, it is thought that il-6 also stimulates the 
parvicellular arginine-vasopressin (Avp) and other 
ACth secretagogues. CRh is transported to the pi-
tuitary, where in synergy with vasopressin it stimulates 
the secretion of ACth, which in turn stimulates the 
adrenal cortex to secrete cortisol67,68. An elevated level 
of cortisol in normal conditions establishes control by 
the negative feedback mechanism and inhibits the se-
cretion of tnf-α, il-1 and il-6 in immune cells, 
ACth in the pituitary, and CRh in the hypothala-
mus68. however, it seems that there is impairment in 
the regulation of this inhibitory feedback mechanism 
that normally reduces hyperactivity of the hpA axis 
in depressive disorder66. during chronic stress and de-
pression, the concentration of proinflammatory cytok-
ines grows despite the hypersecretion of cortisol. This 
suggests that the glucocorticoid receptors on immune 
cells are hypofunctional in patients with depression 
and cortisol cannot suppress many components of cel-
lular immunity. studies in patients with depression 
have shown that these glucocorticoid receptors are 
less sensitive but return to normal after effective treat-
ment67. elevated levels of cytokines further interfere 
with the negative feedback mechanism to increasing 
the resistance of corticosteroid receptors in the hypo-
thalamus and pituitary. furthermore, activation of 
ido induced by cytokines may also be involved in the 
attenuation mechanism of negative feedback through 
the production of kynurenine metabolites (Quin), 
which by acting on nMdA receptors may cause hip-
pocampal atrophy and loss of corticosteroid receptors. 
Thus, elevated levels of Quin may represent an ad-
ditional mechanism by which cytokines can disrupt 
the negative feedback mechanism causing hyperac-
tivity of hpA axis. however, it should be noted that 
30%-50% of depressed patients do not show signs of 
hpA axis hyperactivity. on the other hand, changes 
in the synthesis of cytokines in the periphery can be 
caused by neuroendocrine influence on the immune 
system. in this sense, most important are the effects of 
cortisol, which is synthesized in the adrenal cortex as 
the final product of hpA axis. Cortisol is involved in 
the regulation of immune responses, and through it in 
the synthesis of cytokines. While low concentrations 
of cortisol stimulate the synthesis of cytokines, high 
concentrations are immunosuppressive66.
Depression and the Metabolic Syndrome
depression is a complex disease associated with 
changes in sleep, appetite, body weight and level of 
physical activity, which can be risk factors for the 
development of metabolic disorders. depression can 
contribute to the pathogenesis of the metabolic syn-
drome in the physiological (hpA axis, noradrenergic 
deregulation) and behavioral (smoking, diet, inactiv-
ity, sleep) mechanisms37,92-94. it is possible that meta-
bolic syndrome is a link between depression and both 
cardiovascular disease and diabetes on the other side. 
it is believed that chronic stress causes depression and 
consequential bad lifestyle that can lead to metabolic 
syndrome and subsequent development of cardiovas-
cular disease94. hpA axis dysregulation is typically 
linked to chronic stress, and numerous studies have 
described such an association between depression and 
high cortisol levels96-98. on the other hand, elevated 
levels of cortisol are associated with components of 
metabolic syndrome such as abdominal obesity and 
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glucose intolerance, thus depression may indirectly 
affect glucose metabolism and the risk of developing 
diabetes33,99. Moreover, psychosocial variables such as 
depressed mood can lead to changes in the levels of 
proinflammatory cytokines that are also important 
components in the development of metabolic syn-
drome100. There is ample evidence that depression is 
accompanied by changes in the immune system, par-
ticularly in terms of imbalance between proinflamma-
tory and anti-inflammatory cytokines76,101,102. CRp is 
an acute phase protein and a nonspecific marker of 
systemic inflammation that is elevated in depression 
and metabolic syndrome103,104. il-6 is elevated in de-
pression and positively correlated with obesity and hy-
pertension105,106. tnf-α reflects the clinical course of 
depression, and its expression is increased in adipose 
tissue of the obese107,108.
based on previous researches, we can say that de-
pressed patients, who are in a high percentage over-
weight, have a higher incidence of cardiovascular dis-
ease, hypertension and diabetes than other psychiatric 
patients and the general population109-125. depressive 
symptoms were associated with individual compo-
nents of metabolic syndrome in male twins aged 63126. 
Among middle-aged women, depressive symptoms 
were associated with an increased risk of developing 
metabolic syndrome 7 years later109. Women with a 
history of depression are at a twofold risk of develop-
ing metabolic syndrome when compared with others. 
There was no association found between depression 
and metabolic syndrome in young finnish subjects127, 
while it was found in younger women but not in men 
in the united states128. The results of two longitudinal 
studies of middle-aged women show predictability of 
depressive symptoms for the development of meta-
bolic syndrome109,129. in a recent review from 2007, 
Jakovljević et al. report that 24.6% to 50% of bipo-
lar patients and 12%-36% of patients with depression 
have metabolic syndrome1.
symptoms of depressive disorders are common 
in patients with metabolic syndrome, and fatigue is 
a common symptom in conditions of chronic activa-
tion of nonspecific immunity, such as metabolic syn-
drome128,130-133. A number of components of metabolic 
syndrome and individual components such as obesity, 
diabetes, hyperglycemia, hypertriglyceridemia and 
hypertension were correlated with depressive symp-
toms and with the likelihood of depression develop-
ment99,123,128,134,135. The mechanisms responsible for the 
development of depressive symptoms in patients with 
metabolic syndrome are not yet understood; how-
ever, the results of some studies suggest that chroni-
cally activated inflammatory processes in metabolic 
syndrome may participate in the changes of mood. 
There is evidence of low tryptophan serum levels in 
the obese. The obese have increased tryptophan deg-
radation caused by chronic immune activation, which 
further results in a reduced synthesis of serotonin. se-
rotonin is an important biochemical regulator of the 
balance between hunger and satiety and regulates the 
intake of carbohydrates and fats. Carbohydrates raise 
serotonin levels in the brain in patients with mood 
disorders, and excessive carbohydrate intake improves 
mood and state of well being. This quantitative defi-
ciency of serotonin caused by chronic immune stim-
ulation in the obese can lead to a reward deficiency 
syndrome and the consequent pathologic eating as a 
compensatory mechanism for reduced levels of neu-
rotransmitters, enabling support for a functional link 
with obesity. depressive symptomatology in patients 
with metabolic syndrome is primarily associated with 
neurovegetative features such as fatigue, loss of energy 
and anhedonia, and to a lesser extent with mood and 
cognitive symptoms38,86-89,136.
however, the relationship between depression and 
metabolic syndrome, with respect to the question of 
whether depression is a cause, consequence or simple 
marker of the metabolic syndrome, is still a subject of 
controversy1. further prospective studies are needed 
to clarify the possible causal relationship between 
depression and metabolic syndrome and its individ-
ual components, or whether the metabolic syndrome 
precedes depression or depression precedes meta-
bolic syndrome. Moreover, it is important to explore 
the possibility of the existence of a common biologic 
mechanism in the pathogenesis of these two disor-
ders, in which special attention should be paid to dis-
orders of the immune system, especially the possible 
specific mechanisms by which cytokines can induce 
and maintain depressive symptoms and metabolic dis-
orders. As stated earlier, depression plays an impor-
tant role in the pathogenesis of cardiovascular disease, 
a large number of depressive patients meet the criteria 
for metabolic syndrome, and somatic consequences of 
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metabolic syndrome are numerous with the possible 
fatal outcome. The World health organization pre-
dicts that depression will be the second cause of dis-
ability by 2020137. The data presented here emphasize 
the importance of timely recognition and treatment of 
depressive disorders with consequent reduction in the 
incidence of metabolic syndrome, but also the need 
to regularly search for metabolic disorders and their 
treatment to avoid all of these adverse effects and pos-
sibly reduce the incidence of depressive disorders.
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sažetak
MetAboličKi sindRoM, AKtivnost osi hipotAlAMus-hipofiZA-nAdbubReŽnA ŽliJeZdA 
i MediJAtoRi upAle u depResivnoM poReMećAJu
M. Martinac, D. Pehar, D. Karlović, D. Babić, D. Marčinko i M. Jakovljević
depresija je povezana s različitim kardiovaskularnim rizičnim čimbenicima kao što su hipertenzija, pretilost, atero-
gena dislipidemija i hiperglikemija. u depresivnom poremećaju su uočeni hiperaktivnost osi hipotalamus-hipofiza-nad-
bubrežna žlijezda (hhn) i promjene u imunom sustavu. s druge strane, somatske bolesti kao što su pretilost, hiperli-
pidemija, hipertenzija i dijabetes melitus tipa 2 sada se shvaćaju kao važna komorbidna stanja u bolesnika s depresijom. 
patogeneza metaboličkog sindroma i depresije je složena i nedovoljno istražena. smatra se da interakcija kroničnog stresa, 
psihotraume, hiperkortizolizma i poremećene funkcije imunog sustava može doprinijeti razvoju ove bolesti. Cilj ovoga 
istraživanja bio je ispitati odnos između depresije i metaboličkog sindroma u odnosu na disfunkciju osi hhn i promjene 
u upalnim procesima. pretraživanje literature na Medlineu i drugim bazama podataka obuhvaćalo je radove na engleskom 
jeziku objavljene između 1985. i 2012. godine. Analiza literature je provedena pomoću sustavnog pristupa s terminima 
pretraživanja kao što su depresija, metabolički sindrom, upala, citokini, glukokortikoidi, kortizol i os hhn. Zaključno, 
odnos između depresije i metaboličkog sindroma je još uvijek predmet proturječja. potrebne su daljnje prospektivne studije 
u svrhu utvrđivanja moguće uzročno-posljedične veze između depresije i metaboličkog sindroma i njegovih sastavnica. 
nadalje je važno istražiti mogućnost zajedničkog biološkog mehanizma u patogenezi ovih dviju bolesti, pričem pozornost 
treba naročito posvetiti funkcioniranju imunog sustava, a osobito mogućim specifičnim mehanizmima kojima citokini 
mogu inducirati i održavati depresivne simptome i metaboličke poremećaje. podaci izneseni ovdje naglašavaju važnost pre-
poznavanja i liječenja depresivnog poremećaja s posljedičnim smanjenjem učestalosti metaboličkog sindroma, ali potrebu 
redovitog traganja za metaboličkim poremećajima i njihovim liječenjem kako bi se izbjegli svi njihovi negativni učinci i 
tako možda smanjila učestalost depresivnog poremećaja.
Ključne riječi: Depresivni poremećaj; Metabolički sindrom X; Citokini; Hipotalamo-hipofizni sustav
